Search results
Showing 961 to 975 of 1553 results for do not do recommendations
Evidence-based recommendations on naltrexone (Nalorex) for managing opioid dependence in adults.
Recommendation ID NG155/3 Question What is the optimal method for assessing tinnitus in general practice (including consultation...
Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
View recommendations for TA330Show all sections
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)
Evidence-based recommendations on spinal cord stimulation for chronic pain of neuropathic or ischaemic origin in adults.
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.
Recommendation ID NG145/1 Question What is the clinical and cost effectiveness of levothyroxine (T4) and liothyronine (T3) combination
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
Help us improve NICE: take part in research to help us develop better products and services.
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.
Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.